TOB1 Blocks Intestinal Mucosal Inflammation Through Inducing ID2-Mediated Suppression of Th1/Th17 Cell Immune Responses in IBD

Cell Mol Gastroenterol Hepatol. 2022;13(4):1201-1221. doi: 10.1016/j.jcmgh.2021.12.007. Epub 2021 Dec 14.

Abstract

Background & aims: TOB1 is an anti-proliferative protein of Tob/BTG family and typically involved in the tumorigenesis and T cell activation. Although TOB1 is associated with T helper 17 cell-related autoimmunity, its role in modulating T cell-mediated immune responses in IBD remains poorly understood. Here, we explored its expression and the underlying mechanisms involved in the pathogenesis of inflammatory bowel disease (IBD).

Methods: TOB1 and ID2 expression in IBD patients was examined by quantitative real time polymerase chain reaction and immunohistochemistry. IBD CD4+ T cells were transfected with lentivirus expressing TOB1, ID2, TOB1 short hairpin RNA and ID2 short hairpin RNA, respectively, and Tob1-/-CD4+ T cells were transfected with lentivirus expressing Id2. Experimental colitis was established in Tob1-/- mice by trinitrobenzene sulfonic acid enema and in Rag1-/- mice reconstituted with Tob1-/-CD45RBhighCD4+ T cells to further explore the role of Tob1 in intestinal mucosal inflammation. Splenic CD4+ T cells of Tob1-/- mice were sorted to determine transcriptome differences by RNA sequencing.

Results: TOB1 expression was decreased in inflamed mucosa and peripheral blood CD4+ T cells of IBD patients compared with healthy subjects. Overexpression of TOB1 downregulated IBD CD4+ T cells to differentiate into Th1/Th17 cells compared with control subjects. Severe colitis was observed in Tob1-/- mice through trinitrobenzene sulfonic acid enema or in Rag1-/- mice reconstituted with Tob1-/-CD45RBhighCD4+ T cells, compared with control animals. RNA sequencing analysis revealed ID2 as functional target of TOB1 to inhibit IBD CD4+ T cell differentiation into Th1/Th17 cells. Mechanistically, TOB1 was associated with Smad4/5 to induce ID2 expression and restrain Th1/Th17 cell differentiation.

Conclusions: TOB1 restrains intestinal mucosal inflammation through suppressing Th1/Th17 cell-mediated immune responses via the Smad4/5-ID2 pathway. It may serve as a novel therapeutic target for treatment of human IBD.

Keywords: CD4(+) T Cells; ID2; Inflammatory Bowel Disease; Mucosal Inflammation; TOB1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Colitis*
  • Homeodomain Proteins / metabolism
  • Humans
  • Inflammation / pathology
  • Inflammatory Bowel Diseases* / pathology
  • Inhibitor of Differentiation Protein 2 / genetics
  • Inhibitor of Differentiation Protein 2 / metabolism
  • Intestinal Mucosa / metabolism
  • Intracellular Signaling Peptides and Proteins / metabolism*
  • Lymphocyte Activation
  • Mice
  • RNA, Small Interfering / metabolism
  • Sulfonic Acids / metabolism
  • Sulfonic Acids / therapeutic use
  • Th1 Cells
  • Th17 Cells / metabolism
  • Th17 Cells / pathology
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / metabolism

Substances

  • Homeodomain Proteins
  • ID2 protein, human
  • Inhibitor of Differentiation Protein 2
  • Intracellular Signaling Peptides and Proteins
  • RNA, Small Interfering
  • Sulfonic Acids
  • TOB1 protein, human
  • Tob1 protein, mouse
  • Tumor Suppressor Proteins